WO1999065506A3 - Cancer therapy with indolicidin or cationic peptides and their polymer conjugates - Google Patents

Cancer therapy with indolicidin or cationic peptides and their polymer conjugates Download PDF

Info

Publication number
WO1999065506A3
WO1999065506A3 PCT/CA1999/000552 CA9900552W WO9965506A3 WO 1999065506 A3 WO1999065506 A3 WO 1999065506A3 CA 9900552 W CA9900552 W CA 9900552W WO 9965506 A3 WO9965506 A3 WO 9965506A3
Authority
WO
WIPO (PCT)
Prior art keywords
cationic peptides
indolicidin
cancer therapy
polymer conjugates
therapeutics
Prior art date
Application number
PCT/CA1999/000552
Other languages
French (fr)
Other versions
WO1999065506A2 (en
Inventor
Hillel David Friedland
Timothy J Krieger
Robert Taylor
Douglas Erfle
Janet R Fraser
Michael H P West
Original Assignee
Micrologix Biotech Inc
Hillel David Friedland
Timothy J Krieger
Robert Taylor
Douglas Erfle
Janet R Fraser
Michael H P West
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micrologix Biotech Inc, Hillel David Friedland, Timothy J Krieger, Robert Taylor, Douglas Erfle, Janet R Fraser, Michael H P West filed Critical Micrologix Biotech Inc
Priority to AU42537/99A priority Critical patent/AU4253799A/en
Publication of WO1999065506A2 publication Critical patent/WO1999065506A2/en
Publication of WO1999065506A3 publication Critical patent/WO1999065506A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions and methods for modifying therapeutics with activated polyoxyalkylenes are provided. Therapeutics that may be modified contain or are derivatized to contain an amino or nucleophilic group. Therapeutics include peptides, proteins, nucleic acids, and the like. In addition, cationic peptides, modified or unmodified, can be used to treat tumors, either alone or in combination with a conventional antineoplastic agent.
PCT/CA1999/000552 1998-06-12 1999-06-14 Cancer therapy with indolicidin or cationic peptides and their polymer conjugates WO1999065506A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU42537/99A AU4253799A (en) 1998-06-12 1999-06-14 Cancer therapy with cationic peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9654198A 1998-06-12 1998-06-12
US09/096,541 1998-06-12

Publications (2)

Publication Number Publication Date
WO1999065506A2 WO1999065506A2 (en) 1999-12-23
WO1999065506A3 true WO1999065506A3 (en) 2000-03-02

Family

ID=22257846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000552 WO1999065506A2 (en) 1998-06-12 1999-06-14 Cancer therapy with indolicidin or cationic peptides and their polymer conjugates

Country Status (2)

Country Link
AU (1) AU4253799A (en)
WO (1) WO1999065506A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777592B2 (en) 2000-04-14 2004-08-17 E.I. Du Pont Denemours And Company Arthropod defensins of Scolopendra canidens, Vaejovis carolinianus, and Argiope spp.
AU2002317071B2 (en) * 2001-06-22 2008-01-31 The Hospital For Sick Children Antimicrobial peptides
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
CA2457885A1 (en) 2001-08-24 2003-03-06 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
DE10201862A1 (en) * 2002-01-18 2003-08-07 Deutsches Krebsforsch Conjugate used to treat prokaryotic infections
WO2006050737A1 (en) * 2004-11-12 2006-05-18 Novozymes A/S Polypeptides having antimicrobial activity and polynucleotides encoding same
GB0517090D0 (en) * 2005-08-19 2005-09-28 Tcp Innovations Ltd ApoE mimetic agents
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
FR2926816B1 (en) 2008-01-25 2010-05-14 Rhodia Operations PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRIL FUNCTIONS
FR2932477B1 (en) 2008-06-17 2013-01-18 Rhodia Operations PROCESS FOR THE PRODUCTION OF NITRILIC COMPOUNDS FROM ETHYLENE-UNSATURATED COMPOUNDS
US9409946B2 (en) 2008-06-17 2016-08-09 Peptisyntha Peptide manufacturing process
FR2937321B1 (en) 2008-10-21 2010-10-22 Rhodia Operations PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRIL FUNCTIONS
FR2941455B1 (en) 2009-01-29 2011-02-11 Rhodia Operations PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRIL FUNCTIONS
WO2020162582A1 (en) * 2019-02-08 2020-08-13 Maruho Co., Ltd. Methods of treating non-virally-induced cancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022338A1 (en) * 1994-02-16 1995-08-24 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
WO1998007745A2 (en) * 1996-08-21 1998-02-26 Micrologix Biotech, Inc. Compositions and methods for treating infections using analogues of indolicidin
WO1998032466A1 (en) * 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
WO1999043357A1 (en) * 1998-02-25 1999-09-02 Micrologix Biotech Inc. Indolicidin and cationic peptides conjugated with polymers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022338A1 (en) * 1994-02-16 1995-08-24 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
WO1998007745A2 (en) * 1996-08-21 1998-02-26 Micrologix Biotech, Inc. Compositions and methods for treating infections using analogues of indolicidin
WO1998032466A1 (en) * 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
WO1999043357A1 (en) * 1998-02-25 1999-09-02 Micrologix Biotech Inc. Indolicidin and cationic peptides conjugated with polymers

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Cationic antimicrobial peptides", R.E.W. HANCOCK LABORATORY, 9 February 1997 (1997-02-09), www.interchg.ubc.ca/bobh/peptides.htm, pages 1 - 2, XP002108189 *
CIRIONI O. ET AL: "In vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii", J ANTIMICROBIAL CHEMOTHERAPY, vol. 42, no. 4, October 1998 (1998-10-01), pages 445 - 451, XP002108358 *
DELGADO C ET AL: "POLYMER-DERIVATIZED PROTEINS: ANALYTICAL AND PREPARATIVE PROBLEMS", PHARMACEUTICAL SCIENCES, vol. 3, no. 1, 1 January 1997 (1997-01-01), pages 59 - 66, XP002068522 *
FALLA T J ET AL: "MODE OF ACTION OF THE ANTIMICROBIAL PEPTIDE INDOLICIDIN", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 32, 9 August 1996 (1996-08-09), pages 19298 - 19303, XP002053993 *
HANCOCK R E W ET AL: "Cationic peptides: a new source of antibiotics", TRENDS IN BIOTECHNOLOGY, vol. 16, no. 2, 1 February 1998 (1998-02-01), pages 82-88, XP004107047 *
HANCOCK R E W: "Peptide antibiotics", LANCET, vol. 349, 8 February 1997 (1997-02-08), pages 418 - 422, XP002108435 *
LADOKHIN A. S. ET AL: "CD spectra of indolicidin antimicrobial peptides suggest turns, not polyproline helix", BIOCHEMISTRY, vol. 38, 27 August 1999 (1999-08-27), pages 12313 - 12319, XP002125627 *
LIM Y. ET AL: "Synthesis and biological characterization of indolicidin analogues", J. BIOCHEM. MOL. BIOL., vol. 30, no. 3, 31 May 1997 (1997-05-31), pages 229 - 233, XP002125626 *
NATHAN A ET AL: "STRATEGIES FOR COVALENT ATTACHMENT OF DOXORUBICIN TO POLY (PEG -LYS), A NEW WATER-SOLUBLE POLY(ETHER URETHANE)", JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, vol. 9, no. 3, 1 July 1994 (1994-07-01), pages 239 - 251, XP002062902 *
RADERMACHER S. W. ET AL: "Bactenecin, a leukocytic antimicrobial peptide, is cytotoxic to neuronal and glial cells", J. NEUROSCIENCE, vol. 36, no. 6, 15 December 1993 (1993-12-15), pages 657 - 662, XP002125625 *
TOPCHIEVA I N ET AL: "SYNTHESIS AND PHYSICOCHEMICAL PROPERTIES OF PROTEIN CONJUGATES WITHWATER-SOLUBLE POLY(ALKYLENE OXIDES)", BIOCONJUGATE CHEMISTRY, vol. 6, no. 4, 1 July 1995 (1995-07-01), pages 380 - 388, XP000517226 *

Also Published As

Publication number Publication date
WO1999065506A2 (en) 1999-12-23
AU4253799A (en) 2000-01-05

Similar Documents

Publication Publication Date Title
WO1999065506A3 (en) Cancer therapy with indolicidin or cationic peptides and their polymer conjugates
EP2283867A3 (en) Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO1998040401A3 (en) Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
AU6357900A (en) Hyaluronic acid-protein conjugates, pharmaceutical compositions and related methods
IL157993A0 (en) Molecular conjugates for use in cancer treatment and methods for the preparation thereof
ZA975211B (en) Compositions and methods for administering borrelia DNA.
DE69835201D1 (en) Neoglycoproteine
EP0809997A3 (en) Medical device with biomolecule-coated surface graft matrix
WO2001053354A3 (en) Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
AU4903101A (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
ZA200204603B (en) Amphiphilic polymers and polypeptide conjugates comprising same.
IL206604A (en) Transmembrane protein, 24p4c12, expressed in prostate cancer, immunogenic compositions comprising them and uses thereof
AU3294297A (en) Marking tumors and solid objects in the body with ultrasound
EE03858B1 (en) Conjugates, their use in prostate cancer drugs, pharmaceutical composition and its preparation
WO2003045309A3 (en) Peptides, peptide compositions,and methods of use in binding p 185
AU2407899A (en) Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
EP0819758A3 (en) Cationic vehicle: DNA complexes and their use in gene therapy
AU1233701A (en) Methods and compositions for treating atheroma, tumors and other neoplastic tissue
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
EP1783140A3 (en) Neovascular-specific peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA